A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype

• Published in: Oncogene 2018-08, Vol.37 (32), p.4372-4384
• Main Authors: Kota, Smitha, Hou, Shurong, Guerrant, William, Madoux, Franck, Troutman, Scott, Fernandez-Vega, Virneliz, Alekseeva, Nina, Madala, Neeharika, Scampavia, Louis, Kissil, Joseph, Spicer, Timothy P.
• Format: Article
• Language: English
• Subjects: 3-D movies; 631/154/1435/2417; 631/67/395; Antineoplastic Agents - pharmacology; Apoptosis; Cancer; Cancer genetics; Cancer research; Carcinogenesis; Cell Biology; Cell culture; Cell Culture Techniques; Cell Line, Tumor; Cell proliferation; Colon; Colon cancer; Colorectal cancer; Drug Screening Assays, Antitumor - methods; Gastrointestinal diseases; Gene mutation; Genetic aspects; Health aspects; High-throughput screening; Human Genetics; Humans; Internal Medicine; K-Ras protein; Medicine; Medicine & Public Health; Molecular targeted therapy; Mutation - genetics; Oncology; Pancreas; Phenotype; Phenotypes; Proscillaridin - pharmacology; Proteins; Proto-Oncogene Proteins p21(ras) - genetics; Signal Transduction - genetics; Tumor cells; Tumors
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/s41388-018-0257-5

The RAS proteins are the most frequently mutated oncogenes in cancer, with highest frequency found in pancreatic, lung, and colon tumors. Moreover, the activity of RAS is required for the proliferation and/or survival of these tumor cells and thus represents a high-value target for therapeutic development. Direct targeting of RAS has proven challenging for multiple reasons stemming from the biology of the protein, the complexity of downstream effector pathways and upstream regulatory networks. Thus, significant efforts have been directed at identifying downstream targets on which RAS is dependent. These efforts have proven challenging, in part due to confounding factors such as reliance on two-dimensional adherent monolayer cell cultures that inadequately recapitulate the physiologic context to which cells are exposed in vivo. To overcome these issues, we implemented a high-throughput screening (HTS) approach using a spheroid-based 3-dimensional culture format, thought to more closely reflect conditions experienced by cells in vivo. Using isogenic cell pairs, differing in the status of KRAS , we identified Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRas G12V allele. Significantly, the identification of Proscillaridin A was facilitated by the 3D screening platform and would not have been discovered employing standard 2D culturing methods.